Jounce Therapeutics, Inc. (JNCE) financial statements (2022 and earlier)

Company profile

Business Address 780 MEMORIAL DRIVE
CAMBRIDGE, MA 02139
State of Incorp. DE
Fiscal Year End December 31
SIC 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments178,566206,478168,843189,874235,652
Cash and cash equivalents95,529147,49353,24147,90623,559
Short-term investments83,03758,985115,602141,968212,093
Receivables   41417,706
Prepaid expense   1,9212,196
Other current assets    43
Other undisclosed current assets12,2614,9134,854  
Total current assets:190,827211,391173,697192,209255,597
Noncurrent Assets
Operating lease, right-of-use asset11,87714,85617,615
Property, plant and equipment4,8827,33610,67213,54016,151
Long-term investments and receivables41,6576,7101,6015,99022,199
Long-term investments41,6576,7101,6015,99022,199
Other noncurrent assets3,4533,9432,2972,7132,713
Total noncurrent assets:61,86932,84532,18522,24341,063
TOTAL ASSETS:252,696244,236205,882214,452296,660
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities15,14114,08011,36710,22411,303
Accounts payable1,6742,0362,4603,2722,849
Accrued liabilities13,46712,0448,9076,9528,454
Deferred revenue 1,931 
Debt  2,901  
Deferred rent credit   61
Deferred revenue and credits51,203
Contract with customer, liability55,157
Other liabilities624213210445
Other undisclosed current liabilities3,6953,271   
Total current liabilities:18,89819,32414,40065,54662,551
Noncurrent Liabilities
Long-term debt and lease obligation9,99313,61816,889  
Operating lease, liability9,99313,61816,889
Liabilities, other than long-term debt   44,77767,000
Deferred revenue and credits66,973
Contract with customer, liability42,715
Deferred rent credit   2,062
Other liabilities    27
Other undisclosed noncurrent liabilities(9,993)(13,618)   
Total noncurrent liabilities:9,99313,61816,88944,77767,000
Total liabilities:28,89132,94231,289110,323129,551
Stockholders' equity
Stockholders' equity attributable to parent223,805211,294174,593104,129167,109
Common stock5142343332
Additional paid in capital465,865362,270281,664268,081257,101
Accumulated other comprehensive income (loss)(238)(17)54(78)(409)
Accumulated deficit(241,873)(151,001)(107,159)(163,907)(89,615)
Total stockholders' equity:223,805211,294174,593104,129167,109
TOTAL LIABILITIES AND EQUITY:252,696244,236205,882214,452296,660

Income statement (P&L) ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
Revenues26,90762,339147,87265,20171,644
Revenue, net71,644
Revenue from related parties26,90762,339147,87265,201
Gross profit:26,90762,339147,87265,20171,644
Operating expenses(117,963)(107,456)(95,055)(96,495)(90,859)
Operating income (loss):(91,056)(45,117)52,817(31,294)(19,215)
Nonoperating income
(Other Nonoperating income)
1991,2894,0523,9612,808
Income (loss) from continuing operations before income taxes:(90,857)(43,828)56,869(27,333)(16,407)
Income tax expense(15)(14)(46)(46)(36)
Net income (loss) attributable to parent:(90,872)(43,842)56,823(27,379)(16,443)
Other undisclosed net loss available to common stockholders, basic    (794)
Net income (loss) available to common stockholders, diluted:(90,872)(43,842)56,823(27,379)(17,237)

Comprehensive Income ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
Net income (loss):(90,872)(43,842)56,823(27,379)(16,443)
Comprehensive income (loss):(90,872)(43,842)56,823(27,379)(16,443)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(221)(71)13233124
Comprehensive income (loss), net of tax, attributable to parent:(91,093)(43,913)56,955(27,048)(16,419)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: